Full-Time

Full Stack Developer

Posted on 9/15/2025

Waltz Health

Waltz Health

11-50 employees

Prescription price comparison marketplace

No salary listed

Chicago, IL, USA

Hybrid

Category
Software Engineering (1)
Requirements
  • 3+ years of experience in a full-time development role. Academic projects and/or side projects may be considered as well.
  • BS in Computer Science or equivalent combination of technical education and work experience.
  • Proficient in .NET (C#) and Python for backend development.
  • Proven experience with Terraform for infrastructure as code.
  • Strong hands-on experience with Azure Data Factory, DBT, Talend and other data ingestion/ETL tools.
  • Comfortable working in an Agile and DevOps environment.
  • Strong knowledge of SQL and relational databases (Postgres and snowflake).
  • Hands-on experience building and maintaining cloud-based applications on Microsoft Azure.
  • Exposure to AI/ML frameworks or cloud-based AI services (e.g., Azure Cognitive Services, OpenAI, TensorFlow, etc.).
Responsibilities
  • Lead application development for our cash card products.
  • Work across technology and business organizations to ensure requirements are well understood such that we can have a continuous development roadmap.
  • Provide L3/L4 support as user issues are escalated.
  • Review all customer feedback to enhance our ongoing roadmap.
  • Work with clients as required for custom requirements.
Desired Qualifications
  • Experience with JavaScript frameworks like React or Angular is highly desirable
  • CSS3, HTML5, Jenkins, Docker, Kubernetes
  • Masters preferred

Waltz Health operates a pharmaceutical marketplace that helps consumers save money on prescription medications. It enables shoppers to search for and compare prices across multiple pharmacy discount cards through its Complete Cash Card Solution with Marketplace Search, then directs them to participating pharmacies. Revenue comes from partnerships with pharmacies and other supply-chain stakeholders, who gain consumer traffic from Waltz Health’s platform. Unlike more opaque systems, Waltz Health focuses on price transparency and a streamlined process by combining healthcare expertise with technology to connect buyers with affordable prescription options. The company’s goal is to simplify obtaining medications, lower costs, and give consumers and pharmacies a clearer, efficient marketplace for prescription pricing.

Company Size

11-50

Company Stage

Series A

Total Funding

$35.4M

Headquarters

Chicago, Illinois

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • EVERSANA merger in August 2025 expands Waltz's commercialization reach globally.
  • True Rx partnership on February 25, 2026, delivers GLP-1 net-price reductions.
  • Serve You Rx integration since May 2025 cuts specialty drug costs over $300B market.

What critics are saying

  • PBM giants CVS and UnitedHealth undercut Waltz via exclusive formularies within 12 months.
  • Novo Nordisk restricts GLP-1 supply to direct channels, collapsing pricing in 18 months.
  • EVERSANA integration fails, diluting Waltz's payer model with pharma conflicts by 2027.

What makes Waltz Health unique

  • Waltz Health deploys AI-driven marketplaces for transparent prescription pricing.
  • Waltz Connect intelligently routes patients to optimal specialty pharmacies.
  • Direct-to-employer GLP-1 pricing bypasses traditional rebate-driven PBMs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive compensation

Stock options

Flexible vacation

Medical, dental, vision

401k

Commuter benefits

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

5%
TrueRx
Feb 25th, 2026
True Rx Health Strategists Collaborates with Waltz Health to Provide Direct-to-Employer, Industry-Leading GLP-1 Pricing

True Rx Health Strategists collaborates with Waltz Health to provide direct-to-employer, industry-leading GLP-1 pricing. February 25, 2026 New direct model delivers an in-network pathway for GLP-1 access WASHINGTON, IN and CHICAGO, February 25, 2026 - True Rx Health Strategists today announced an innovative, first-to-market pharmacy benefit manager (PBM) collaboration with Waltz Health, an EVERSANA company, that will deliver direct-to-employer pricing on select GLP-1 medications. The collaboration between True Rx and Waltz Health is focused on a common purpose to make medications more affordable and signals a transformative moment for employer-sponsored health care. The new model will be offered to True Rx employer clients in 2026, embedding direct-to-employer GLP-1 pricing within employers' existing pharmacy benefits through an integrated, in-network solution with Waltz Health. Health care costs continue to rise while quality of care declines, and employers are urgently seeking better solutions to reverse this trajectory. True Rx, the pharmacist-owned, patient-first PBM, is responding by introducing new programs that deliver innovation, transparency, and industry-leading pricing. Under this new model, employers will be able to provide access to select GLP-1 weight loss medications, including Wegovy(R) and Zepbound(R), at select pharmacies at significantly reduced prices. The prices will be seamlessly integrated into each member's experience and applied to their deductible and out-of-pocket max. This represents a true net-price reduction strategy for payers - free from rebate pressures. GLP-1 medications have rapidly become gamechangers for weight management, but their high cost has made sustainable access challenging for employers and their employees. The collaboration sets a new precedent for affordability, access, and patient-centered care. "The health care industry can't keep doing things the same way and expect change. We're paving a new path forward, taking bolder steps to do the right thing for our patients," said Adrienne Williams LaBorwit, True Rx's new Chief Executive Officer as of January 1, 2026. "GLP-1 pricing has been distorted by opaque supply chains, rebate-driven incentives, and misaligned economics that don't serve employers or patients," said Jeff Park, President of Waltz Health. "This collaboration with True Rx creates a fundamentally different model that delivers real net-price reductions through direct, in-network access, not financial engineering. By connecting employers to transparent pricing and high-value pharmacy networks, we're helping make sustainable access to GLP-1s possible at scale, while restoring trust, affordability, and integrity to how these medications are priced and delivered." Employers adopting this model can amplify its impact by pairing the new pricing solution with True Rx's wraparound True Outcomes: Weight Management program, which launched this year. This holistic approach combines affordable medication access with comprehensive lifestyle guidance for better health. Together, these solutions support sustainable results and long-term health transformation. Designed to reduce reliance on medications like GLP-1s while maintaining weight loss, True Rx's pilot program achieved 6-15% average weight loss. "Fundamental change is needed and that starts with every PBM. This includes offering clinical programs combined with reduced medication pricing to support better health outcomes," said Williams LaBorwit. "Employers must demand better for their people. Every employer who chooses a better path sends an unmistakable message to the pharmacy benefit industry that business as usual is no longer acceptable." About True Rx Health Strategists True Rx Health Strategists is a pharmacy benefits manager for self-funded plans nationwide who refuse to accept the health care paradox: spending more on pharmacy benefits while employees get sicker. As Health Strategists, True Rx delivers transparent pricing and proactive, pharmacist-led solutions guided by clinical expertise, not financial incentives. Through health innovation, True Rx addresses America's biggest health challenges including diabetes, obesity, and mental health. True Rx delivers the True Experience by going the extra mile for every employer and every patient with personalized support and exceptional care. True Rx is an Inc. 5000 Fastest-Growing Private Company. Learn more at truerx.com. About Waltz Health Waltz Health, an EVERSANA company, develops technologies and services that support better-informed decisions on prescription care. Designed for payers, pharmacies, pharmacy benefit managers, and self-insured employers, the company offers AI-driven marketplaces to lower overall drug costs, providing better pricing options and more information for consumers while also helping payers take control of their pharmacy benefits. For more information, visit www.waltzhealth.com. MEDIA CONTACTS: * Julie Goulette: 612-968-3544 * Jenna Elving, 612-306-9518 * [email protected] As Health Strategists, True Rx, LLC. is a new PBM category of clinically trained partners that take a patient-first approach to health care and cost management.

Arkansas Democrat-Gazette
Aug 27th, 2025
Eversana acquires Waltz Health

Eversana, a company that helps drugmakers sell their medicines, has acquired a smaller firm called Waltz Health that helps employers and health insurance companies purchase cheaper drugs, in a bid to build an alternative to traditional pharmacy benefits middlemen in the U.S.

PharmaLive
Aug 26th, 2025
EVERSANA Merges with Waltz Health

EVERSANA merges with Waltz Health.

PR Newswire
Aug 26th, 2025
EVERSANA and Waltz Health Merge

EVERSANA has merged with Waltz Health to form a new healthcare platform aimed at transforming pharmaceutical commercialization and patient access. The merger combines Waltz Health's software-driven drug-price marketplaces and direct-to-payer model with EVERSANA's global commercialization services. Mark Thierer, Co-founder and CEO of Waltz Health, will become CEO of EVERSANA, while former CEO Jim Lang will remain as a board member.

pharmaphorum
Aug 26th, 2025
EVERSANA buys digital drug-price marketplace firm Waltz Health

Waltz Health CEO and cofounder and new EVERSANA CEO Mark Thierer speaks on a panel at HLTH 2022.

INACTIVE